Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
- 23 March 2022
- journal article
- research article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (7) , 991-994
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 13 references indexed in Scilit:
- Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseasesAnnals of the Rheumatic Diseases, 2021
- Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal AntibodiesClinical Infectious Diseases, 2021
- Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody CocktailViruses, 2021
- Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 PathogenesisMolecules and Cells, 2021
- Neutralizing monoclonal antibodies for treatment of COVID-19Nature Reviews Immunology, 2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)Nature Communications, 2021
- High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive studyRheumatology International, 2020
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodiesScience, 2020
- Humoral Immune Responses in COVID-19 Patients: A Window on the State of the ArtFrontiers in Immunology, 2020